Wechsler's research focuses on clinical and translational asthma, with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome, or CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. He has published more than 185 peer-reviewed manuscripts relating to asthma, CSS, and eosinophilic lung diseases in multiple journals, including NEJM, JAMA, Lancet, AJRCCM, Chest, and JACI. He is a Steering Committee member and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multi-center asthma clinical trials consortium, and of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation, he has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society, and the International Eosinophil Society. He is currently Associate Editor of the journal Chest, and is on the editorial board of the European Journal of Clinical Investigation. He has previously served as Associate Editor of the journal Allergy.